Lenvima® (lenvatinib) launched in the UK on June 9, a treatment option for people with radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC).1 Advanced thyroid cancer is a difficult to treat condition with a poor prognosis and lenvatinib represents a significant step forward for patients in the UK.
...cont/d in link.